Lobeline

DRUG3 trials

Sponsors

National Institute on Drug Abuse (NIDA)

Conditions

Amphetamine-Related DisordersMethamphetamine Dependence

Phase 1

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

National Institute on Drug Abuse (NIDA)Amphetamine-Related Disorders

Start: 2004-09-30End: 2005-04-30Target: 8Updated: 2017-01-11

Ph1 Lobeline Interaction Study - 1

National Institute on Drug Abuse (NIDA)Methamphetamine Dependence

Target: 10Updated: 2017-01-11

Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

National Institute on Drug Abuse (NIDA)Methamphetamine Dependence

Start: 2006-02-28Target: 12Updated: 2017-01-11